GammaCan International, Inc. (GCAN.OB) Release: VitiGam(TM) Inhibits Melanoma Growth in a Dose Dependent Manner
8/11/2008 8:19:16 AM
KIRYAT ONO, Israel & NEW YORK--(BUSINESS WIRE)--GammaCan International, Inc. (“GammaCan” or “the Company”) (OTCBB: GCAN), a developer of proprietary immunotherapies for the treatment of melanoma and other cancers, today announced further progress in its VitiGam™ development program. In preparation for its upcoming IND submission for VitiGam™, the Company successfully completed additional experiments using its established mouse melanoma model. These studies demonstrate a dose response of tumors (human melanoma cells) when treated with IgG preparations derived from vitiligo donors. In addition, the Company has conducted a meta-analysis (a statistical analysis of a large number of experiments) based on a series of previously announced studies with its mouse melanoma model. The results of this meta-analysis further confirm the effectiveness against melanomas of IgG preparations derived from vitiligo donors.
comments powered by